RLFTF   $8.6  7.50% Market Closed

Relief Therapeutics Holding AG
Last Events:

2023-05-06 Trend pattern changed from канал to расходящийся клин с наклоном вниз.

2023-05-06 Signal in MACD changed from bearish weakening to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-05-06 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: exit from the overbought zone.

2023-05-06 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-05-04 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-05-04 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-05-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-05-02 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 8.29
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi Sell Sell -
macd - Sell -
stoch Sell - -
ma20 Sell Sell -
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternMay 3, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CH0100191136
ceo Ms. Michelle Lock
Website https://www.relieftherapeutics.com
Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution, that is in Phase I clinical trial to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. Further, it is developing RLF-OD32, which is in Phase I clinical trial for the treatment of patients with phenylketonuria; and. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.